A CRISPR-Cas9 platform for primary human hepatocytes enables arrayed screening and in vivo validation of HBV host factors
Stenzel, A. F.; Athanasiadis, A.; Dangas, G.; Park, P.; Maslarinou, A.; Moschogianni, E.; Cataneo, A. H. D.; Freije, C. A.; Zhou, Y.; Levenson, K. C.; Quirk, C.; Zou, C.; Schneider, W. M.; Aguzzi, A.; Rice, C. M.; de Jong, Y. P.; Michailidis, E.
Show abstract
More than two million deaths annually are attributed to liver-related conditions, making primary human hepatocytes (PHH) an invaluable in vitro model for studying liver pathophysiology and the molecular mechanisms underlying hepatic diseases. However, because PHH do not proliferate in culture, CRISPR gene editing has been highly inefficient. Here, we report lipofection- and lentivirus-mediated protocols for CRISPR-Cas9 delivery in mouse-passaged primary human hepatocytes (mpPHH), a system that enables PHH expansion in liver-humanized mice. We achieve robust gene editing efficiencies exceeding 90% in mpPHH while maintaining cell viability. We demonstrate the utility of these protocols by disrupting CYP3A4 to impair xenobiotic metabolism and by showing that edited mpPHH efficiently engraft and expand in mice, generating liver-humanized animals. We establish the feasibility of arrayed CRISPR screening in mpPHH using an 85-gene screen to identify host factors influencing hepatitis B virus (HBV) infection, and validate key findings in humanized mice by targeting the HBV entry receptor SLC10A1 (NTCP), which reduced viral infection in vivo. Our methodology enables scalable genetic manipulation of mpPHH, opening new avenues for HBV research and liver disease modeling.
Matching journals
The top 10 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Harnessing the power of whole human liver ex situ normothermic perfusion for preclinical AAV vector evaluation 94%
- In vivo lentiviral vector gene therapy to cure hereditary tyrosinemia type 1 and prevent development of precancerous and cancerous lesions 94%
- RNAi-mediated rheostat for dynamic control of AAV-delivered transgenes 93%
Similar papers in this journal
- Discovery and validation of novel human genomic safe harbor sites for gene and cell therapies 90%
- Harmonizing terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) with multiplexed iterative immunofluorescence enriches spatial contextualization of cell death 90%
- Temporal control of sgRNA library activation unlocks large-scale in vivo CRISPR screens 90%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.